SABBY MANAGEMENT, LLC - Q3 2014 holdings

$2.6 Billion is the total value of SABBY MANAGEMENT, LLC's 254 reported holdings in Q3 2014. The portfolio turnover from Q2 2014 to Q3 2014 was 0.0% .

 Value Shares↓ Weighting
 SANGAMO BIOSCIENCES INCcall$10,798,000
-29.4%
10,0120.0%0.42%
-36.6%
 INCYTE CORPcall$2,114,000
-13.1%
4310.0%0.08%
-22.1%
 SEATTLE GENETICS INCcall$784,000
-2.9%
2110.0%0.03%
-14.3%
 ENDOCYTE INCput$525,000
-7.7%
8630.0%0.02%
-16.7%
 ALEXZA PHARMACEUTICALS INCcall$475,000
-49.0%
2,0400.0%0.02%
-55.0%
 PSIVIDA CORPput$393,000
+1.8%
8900.0%0.02%
-11.8%
 PHARMACYCLICS INCput$341,000
+31.2%
290.0%0.01%
+18.2%
 ALIMERA SCIENCES INCput$266,000
-9.2%
4900.0%0.01%
-23.1%
 PSIVIDA CORPcall$155,000
+2.0%
3500.0%0.01%
-14.3%
TROV  TROVAGENE INC$92,000
+31.4%
20,0000.0%0.00%
+33.3%
 GERON CORPput$65,000
+91.2%
1070.0%0.00%
+100.0%
 BIODEL INCput$30,000
-23.1%
1820.0%0.00%
-50.0%
CVM  CEL-SCI CORP$12,000
-25.0%
12,8880.0%0.00%
-100.0%
Other managers

Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):

Original filings

The following EDGAR filing(s) were analyzed to create this report:

  • View 13F-HR/A filed 2014-11-18
Signatures

The EDGAR filing(s) were signed by:

Top long-term holdings
NameQuarters ownedLatest quarter ownedMax weighting
SPDR S&P 500 ETF TRUST UNIT37Q3 202349.1%
ISHARES TR35Q3 202352.2%
SPDR S&P BIOTECHNOLOGY32Q3 202212.8%
AMARIN CORP PLC30Q4 20212.0%
BIOGEN INC24Q1 202126.2%
SAREPTA THERAPEUTICS INC24Q3 20204.6%
BIOGEN INC23Q1 202113.7%
SAREPTA THERAPEUTICS INC22Q3 20206.2%
BRAINSTORM CELL THERAPEUTICS INC21Q3 20231.6%
VERTEX PHARMACEUTICALS INC20Q1 201812.6%

View SABBY MANAGEMENT, LLC's complete holdings history.

Latest significant ownerships (13-D/G)
SABBY MANAGEMENT, LLC Q3 2014 significant holdings filed using form 13D/G when ownership exceeds 5% of a company's total stock issue.
FiledShares Percentage
AGM GROUP HOLDINGS, INC.January 10, 2023627,9362.6%
Bit Digital, IncJanuary 10, 20233,166,9173.8%
Cingulate Inc.January 10, 2023105.0%
Context Therapeutics Inc.January 10, 2023796,7065.0%
HeartBeam, Inc.January 10, 2023271,7883.4%
PharmaCyte Biotech, Inc.January 10, 2023934,4565.0%
Rebus Holdings, Inc.Sold outJanuary 10, 202300.0%
TANTECH HOLDINGS LTDJanuary 10, 202341,5000.6%
Quanergy Systems, Inc.January 04, 2023936,9055.8%
TuanChe LtdJanuary 04, 20232,384,71310.0%

View SABBY MANAGEMENT, LLC's complete significant-ownership history.

Latest filings
TypeFiled
13F-HR2024-05-15
13F-HR2024-02-14
SC 13G2024-01-04
SC 13G2024-01-04
SC 13G2024-01-04
SC 13G2024-01-04
SC 13G2024-01-04
SC 13G2024-01-03
SC 13G2024-01-03
SC 13G2024-01-03

View SABBY MANAGEMENT, LLC's complete filings history.

Compare quarters

Issues

The following issues were detected while analyzing the report:

  • The reported has been restated
  • The reported has been amended

Export SABBY MANAGEMENT, LLC's holdings